NASDAQ:VTVT vTv Therapeutics 3/20/2025 Earnings Report $19.84 -0.22 (-1.10%) Closing price 09/12/2025 03:54 PM EasternExtended Trading$20.04 +0.20 (+1.01%) As of 09/12/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast vTv Therapeutics EPS ResultsActual EPS-$0.55Consensus EPS -$0.87Beat/MissBeat by +$0.32One Year Ago EPSN/AvTv Therapeutics Revenue ResultsActual Revenue$0.02 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AvTv Therapeutics Announcement DetailsQuarterDate3/20/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsvTv Therapeutics' next earnings date is estimated for Tuesday, November 11, 2025, based on past reporting schedules. Conference Call ResourcesSEC FilingEarnings HistoryCompany Profile vTv Therapeutics Earnings HeadlinesUPDATE -- vTv Therapeutics to Participate in Upcoming September Investor ConferencesSeptember 3, 2025 | globenewswire.comvTv Therapeutics to Participate in Upcoming September Investor ConferencesSeptember 3, 2025 | globenewswire.comA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for. | Investors Alley (Ad)vTv Pops on Purchase AgreementSeptember 2, 2025 | baystreet.cavTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D FundSeptember 2, 2025 | globenewswire.comvTv Therapeutics Inc.: vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 13, 2025 | finanznachrichten.deSee More vTv Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like vTv Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on vTv Therapeutics and other key companies, straight to your email. Email Address About vTv TherapeuticsvTv Therapeutics (NASDAQ:VTVT), Inc. is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties. The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease. In parallel, vTv is advancing TTP399, a liver-selective glucokinase activator designed as an adjunctive therapy for type 1 diabetes. These programs exemplify vTv’s strategy of targeting high-need indications with differentiated oral therapies. Since its inception, vTv Therapeutics has pursued strategic collaborations and licensing agreements to support its clinical development efforts and potential commercialization. While primarily operating in the United States, the company actively seeks global partnerships to extend the reach of its pipeline. Led by a management team with extensive experience in pharmaceutical research, clinical development and regulatory affairs, vTv remains committed to progressing its candidates through pivotal trials toward regulatory approval.View vTv Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Celsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
